Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. References.
73 
Let's personalize your content